Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROAD: Romosozumab and Denosumab for Osteoporosis
NCT07909304Phase 4Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2027
- Primary completion
- Dec 2030
01
Overview
Phase 4, randomised trial in postmenopausal osteoporosis comparing Romosozumab and denosumab with Romosozumab (2 arms). Primary endpoint: Total hip areal bone mineral density at 12 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
romosozumabdenosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT07909304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909304.